IRLAB Therapeutics AB (publ) (IRLAB-A)
Nasdaq Stockholm · Sweden · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 2.020 |
|---|---|
| 52-week range | 1.145 – 2.720 |
| Return, 1 month / 3 months | +6.3% / +62.1% |
| Return, 1 year / 3 years | −15.4% / −68.3% |
| Trend | Uptrend |
| RSI (14) | 60 |
| Volatility (1 year) | 51.2% |
| Worst drawdown (1 year) | -52.8% |
| Average daily value traded | 2.02M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
IRLAB Therapeutics is a Swedish biopharmaceutical company based in Gothenburg that discovers and develops new medicines for Parkinson's disease. Its work centres on drug candidates that target symptoms and complications of the condition, including movement problems and cognitive difficulties, and it advances these programmes through clinical testing. The company carries out its own research and development and works with partners and clinical investigators to study its compounds in patients.
The shares are listed on the Nasdaq Stockholm in Sweden under the code IRLAB-A, and the price on this page is in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
IRLAB Therapeutics AB (publ) (IRLAB-A) trades on the Nasdaq Stockholm in Sweden. It last closed at SEK 2.020 on 27 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 236 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 15.4% and over the last three months it rose 62.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Stockholm
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 30.2% | ||
| From 52-week high | -18.7% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 62.1% | ||
| 6-month return | 34.2% | ||
| 12-month return, skipping the last month | -20.4% | ||
| Stability (higher is calmer) | 41 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 51.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -52.8% | ||
| Liquidity | 66 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.02M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −2.2% |
|---|---|
| 1 month | +6.3% |
| 3 months | +62.1% |
| 6 months | +34.2% |
| 1 year | −15.4% |
| 3 years | −68.3% |
| 5 years | −94.8% |
Signals
| 50-day / 200-day average | 1.828 / 1.551 |
|---|---|
| Golden / death cross (60 days) | Golden, 27 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.119 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Stockholm; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.